Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521766

SCHEMBL1521766

SCHEMBL1521766

CNc1cc2c(cn1)CN(c1cc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)cc1C)C(=O)N2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 8/20 0.42
▸ MAP4K2 Q12851 8/20 0.42
▸ KDR P35968 6/20 0.42
▸ ABL1 P00519 4/20 0.42
▸ RET P07949 3/20 0.42
▸ PDGFRB P09619 3/20 0.42
▸ NTRK3 Q16288 3/20 0.42
▸ BMX P51813 2/20 0.42
▸ PDGFRA P16234 2/20 0.42
▸ LCK P06239 1/20 0.42
▸ FES P07332 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ FLT1 P17948 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ EPHA3 P29320 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ TEK Q02763 1/20 0.42
▸ KARS1 Q15046 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521678 0.88 KDR (0.40) TNK2MAP4K2KDRABL1RET
SCHEMBL1521979 0.84 RAF1 (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521647 0.84 RAF1 (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521960 0.83 BRAF (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521797 0.83 TNK2 (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521700 0.83 RAF1 (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521631 0.83 RAF1 (0.36) TNK2MAP4K2KDRABL1RET
SCHEMBL1521659 0.83 BRAF (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521543 0.83 RAF1 (0.37) TNK2MAP4K2KDRABL1RET
SCHEMBL1521888 0.83 RAB9A (0.45) RETBRAFMAPK14FLT3MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885KDR 500/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.